Meloxicam
Total Payments
$1.4M
Transactions
15
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $610,320 | 9 | 0 |
| 2021 | $776,696 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 15 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MECC-TBZ-2001 | Mylan Pharmaceuticals Inc. | $776,696 | 0 |
| MELO-TFZ-2002 | Mylan Inc. | $527,324 | 0 |
| MELO-TFZ-2001 | Mylan Inc. | $44,237 | 0 |
| MELO-TFZ-2003 | Mylan Inc. | $38,758 | 0 |
Top Doctors Receiving Payments for Meloxicam
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $1.4M | 15 |
Ad
Manufacturing Companies
- Mylan Pharmaceuticals Inc. $776,696
- Mylan Inc. $610,320
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 0
- Transactions 15
About Meloxicam
Meloxicam is a drug associated with $1.4M in payments to 0 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2021 to 2022. In 2022, $610,320 was paid across 9 transactions to 0 doctors.
The most common payment nature for Meloxicam is "Unspecified" ($1.4M, 100.0% of total).
Meloxicam is associated with 4 research studies, including "MECC-TBZ-2001" ($776,696).